Rivfloza® (Nedosiran) - CAM 966HB
Background
FDA-Approved Indication: Rivfloza (nedosiran) is an RNA interference (RNAi) therapeutic indicated to reduce urinary oxalate levels in children and adults with Primary Hyperoxaluria Type 1 (PH1) and relatively preserved kidney function. Rivfloza targets hepatic lactate dehydrogenase A (LDHA), reducing oxalate production regardless of the underlying AGXT mutation.
Policy (Criteria)
Initial Authorization Criteria
Rivfloza may be considered medically necessary when all of the following criteria are met:
1. Diagnosis of Primary Hyperoxaluria Type 1 (PH1)
2. Disease has been confirmed by both of the following:
- Biochemical evidence of hyperoxaluria demonstrated by one of the following:
- Elevated urinary oxalate excretion
- Elevated plasma oxalate concentration
- Spot urinary oxalate-to-creatinine molar ratio greater than normal for age
- Confirmation of PH1 by one of the following:
- Genetic testing demonstrating pathogenic mutation(s) in the alanine:glyoxylate aminotransferase (AGXT) gene
- Liver biopsy demonstrating absent or reduced alanine:glyoxylate aminotransferase (AGT) activity
3. Patient is 2 years of age or older
4. Patient has preserved kidney function (Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m²)
5. Patient has not received a liver transplant
6. Prescribed by or in consultation with one of the following:
- Hepatologist
- Nephrologist
- Urologist
- Geneticist
- Specialist with expertise in the treatment of Primary Hyperoxaluria Type 1
7. Rivfloza will not be used in combination with Oxlumo® (lumasiran)
Authorization Duration: 12 months
Reauthorization Criteria
Rivfloza may be reauthorized when all of the following criteria are met:
1. Patient demonstrates a positive clinical response to therapy examples include one or more of the following:
- Decreased urinary oxalate excretion
- Decreased plasma oxalate concentration
- Normalization or near-normalization of urinary oxalate levels
- Reduction in kidney stone formation
- Reduction in nephrocalcinosis progression
- Stabilization or improvement in kidney function
- Reduction in PH1-related complications
2. Patient has not received a liver transplant
3. Therapy continues to be prescribed by or in consultation with one of the following:
- Hepatologist
- Nephrologist
- Urologist
- Geneticist
- Specialist with expertise in the treatment of Primary Hyperoxaluria Type 1
4. Rivfloza will not be used in combination with Oxlumo® (lumasiran)
Authorization Duration: 12 months
References
- Rivfloza® (nedosiran) Prescribing Information. Novo Nordisk Inc. Current prescribing information.
- U.S. Food and Drug Administration (FDA). Rivfloza (nedosiran) Injection Approval Documentation.
- Garrelfs SF, Frishberg Y, Hulton SA, et al. RNA Interference Therapy for Primary Hyperoxaluria Type 1. New England Journal of Medicine.
- Cochat P, Groothoff JW. Primary Hyperoxaluria Type 1: Practical Clinical Management and Treatment Strategies. Kidney International.
- Hoppe B, Beck BB, Milliner DS. The Primary Hyperoxalurias. Kidney International.
- GeneReviews®. Primary Hyperoxaluria Type 1.
- National Organization for Rare Disorders (NORD). Primary Hyperoxaluria.
- American Society of Nephrology (ASN). Clinical guidance regarding diagnosis and management of primary hyperoxaluria.
Coding Section
| Code |
Number |
Description |
| HCPCS |
J3490 |
Unclassified drugs [when specified as [Rivfloza] (nedosiran)] |
| ICD-10, etc |
E72.530 |
Primary hyperoxaluria, type 1 |
Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each Policy. They may not be all-inclusive.
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.
"Current Procedural Terminology © American Medical Association. All Rights Reserved"
History From 2026 Forward
| 10/01/2026 |
New Policy |